MedPath

Study to Evaluate the Efficacy and Safety of Wound Healing Topical Spray in Patients withDiabetic Foot Ulcer.

Not Applicable
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2022/04/041672
Lead Sponsor
Inzpera Healthsciences Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Male/female of >=18 and <=75 years of age.

2.Patient who can and willing to provide written Informed Consent.

3. Patient with a history of type 2 diabetes mellitus 4.

4.Patient having Random Blood Sugar [RBG] Ë? 250 mg/dL, on standard antidiabetic treatment.

5. Patient having glycosylated hemoglobin (HbA1c) of less than 12% (based on the existing reports).

6.Patient with at least ONE but not more than THREE DFU with wound surface area measured between 1 cm2 and 12 cm2 and depth post-debridement between 1cm2 -2cm2 , on the day of randomization (wound surface area measured by greatest length, greatest width).

7.Patient with ulcer located at or below malleolar region of foot and Superficial ulcer, Ulcer without infection, mild and moderate infection. Stage I-A, II-A or I-B on University of Texas wound classification system.

Exclusion Criteria

1.Patient Ë? 18 or Ë? 75 years of age.

2. Pregnant and/or nursing woman.

3. Patient with more than 3 ulcers.

4. Patient with ulcers measuring wound surface area more than 12 cm2 and depth more than 2cm2.

5. Patient having severe or poorly controlled Type II diabetes mellitus with severe hyperglycemia (RBG more than 250 mg/dL).

6. Patient having HbA1c of more than 12%.

7. Patient with severe ischemia with Ankle-Brachial Index (ABI) <= 0.7.

8. Patient having progressive weight loss.

9. Patient having poor nutritional status (S. albumin less than 2.5g /dL).

10. Patient with ulcer deep into bone and joint or Osteomyelitis or Severe ulcer.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of subjects with complete healing of ulcer. <br/ ><br>Complete healingâ?? will be defined as absence of visible wound by complete epithelialization.[Time Frame: 10 weeks ]Timepoint: 10 weeks
Secondary Outcome Measures
NameTimeMethod
1. Time taken for achieving complete wound closure from the baseline [Time Frame: 10 weeks ] <br/ ><br>2. Change in wound surface area from baseline [ Time Frame: 10 weeks ] <br/ ><br>Mean percent change in wound area from baseline at each visitTimepoint: 10 weeks
© Copyright 2025. All Rights Reserved by MedPath